Recent advancements in single-molecule, long-read sequencing (LRS) technologies, developed by companies such as Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio), have substantially ...

Cell-free DNA (cfDNA) analysis offers a powerful, minimally invasive approach to improve cancer care by measuring tumor-specific genomic and epigenetic alterations. Here, we demonstrate the ...

Researchers from Iwate Medical University and Tohoku University have revealed that it is possible to predict cancer relapse and treatment response by measuring circulating tumor DNA (ctDNA), in tandem ...

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced the publication of a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling ...

Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...

Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma In 2022, 283 patients with NSCLC ...

Promising new inroads into critical DNA testing has been forecast by Flinders University experts who have applied machine learning to DNA profiling. From medical diagnostics to forensic tests and ...

A robust platform for analyzing 3D genome architecture and epigenomic features enables a deeper understanding of gene regulation in specific cell types. Researchers analyze various aspects of gene ...

Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

The retrospective analysis informed the development of a publicly available classifier that will undergo prospective validation next.

The non–small cell lung cancer (NSCLC) cohort results from the FPG500 program are outlined. CGP was performed by TruSight Oncology 500 High Throughput (TSO500HT) assay or Oncomine Focus Assay plus ...